Medical Malpractice Insurance for California Behavioral Health, Ketamine, and TMS Practices

"Ketamine clinic" is not a clinical description. It can mean psychiatric evaluation and medication management, intravenous ketamine, compounded medicine used at home, FDA-approved esketamine under a restricted program, transcranial magnetic stimulation, or some combination of them. The treatments do not share the same product, device, setting, monitoring, controlled-substance, or follow-up requirements.

That is why this practice type needs more than a polished intake form and a broad insurance application. The physician needs a service-by-service account of the care patients receive. For each service, the practice should be able to show who assesses the patient, who makes the treatment decision, who performs the work, what happens during an adverse event, how the patient is followed, and which entity and policy apply.

Begin with the psychiatric care system

The advanced service does not replace the underlying psychiatric practice. Before adding a drug or device program, make the foundation visible: evaluation, diagnosis, medication management, psychotherapy, testing, consultation, telehealth, patient messages, missed visits, crisis response, after-hours coverage, transfer of care, and termination of care.

For each clinician, record the license, actual duties, patient population, locations, authority to prescribe or furnish, training and competency evidence, supervising or practice documents where applicable, and escalation path. California also requires an appropriate prior examination and medical indication before a dangerous drug is prescribed, furnished, or dispensed. A schedule only proves that someone was working. It does not show who could make the clinical decision when a patient deteriorated, missed follow-up, or reported a new safety concern.

Do not collapse nurse practitioners and physician assistants into one generic supervision category. California uses different pathways. A PA's practice agreement and an NP's actual authority and setting should match the work the person performs. For each prescribing or administration role, document the license, setting, education and competency, and applicable NP standardized procedure or PA practice agreement. A title alone does not establish authority for this service. The NP and PA guide explains the distinction.

Separate ketamine from FDA-approved esketamine

Ketamine and esketamine are related names, not interchangeable programs. FDA-approved ketamine products are indicated for induction and maintenance of general anesthesia. The FDA states that ketamine is not approved to treat psychiatric disorders. Psychiatric use therefore needs an intentional clinical operating description rather than the assumption that an anesthesia product creates a psychiatric treatment program.

Start with the exact product and route. Record the source, formulation, route, prescriber, clinician administering or observing the treatment, treatment setting, monitoring, recovery, transport plan, patient instructions, and follow-up owner. Do not use "ketamine therapy" as a catch-all label for intravenous, intramuscular, oral, sublingual, nasal, or other work.

FDA-approved esketamine nasal spray, marketed as Spravato, is a separate product with its own restricted REMS program. Current REMS materials require administration in a REMS-certified health care setting and at least two hours of monitoring after each dose for sedation, dissociation, respiratory depression with pulse oximetry, and vital signs. The REMS directs dispensing only to certified health care settings.

Treat the REMS record as part of the clinical system, not a separate pharmacy task. The practice should know who maintains setting certification, confirms patient enrollment, supervises administration, completes monitoring records, manages shipments, and retains the required documentation. The current REMS documents, not a previous program manual, control the operational details.

Do not treat compounded or mailed ketamine as an office visit by video

The FDA warns about potential risks associated with compounded ketamine products, including oral formulations, for psychiatric disorders. It identifies concerns that include sedation, dissociation, changes in vital signs, abuse and misuse, and the difficulty of monitoring patients outside a clinical setting. Compounded drugs are not FDA-approved, and compounded ketamine is not FDA-approved for a psychiatric indication.

A program that ships a compounded product to a patient is not the same operation as observed treatment in a clinic. Map the whole patient path: identity, assessment, prescribing, pharmacy relationship, dispensing method, patient location, shipment, administration, monitoring plan, caregiver role if any, communications, emergency response, unused medication, and follow-up. This is an operating map, not a claim that every program must use one specific workflow.

Telehealth does not create a different standard of care. California requires the practitioner to obtain and document verbal or written consent before delivering care by telehealth. The Medical Board says that physicians providing care to patients located in California must hold a valid California license. Record the patient's location at the encounter, the licensed clinician, the states served, the platform, privacy and consent process, and the emergency route that can reach the patient where the patient actually is.

California separately regulates internet delivery of dangerous drugs or devices. The person or entity that prescribes, dispenses, furnishes, or causes that work for delivery in California still needs an appropriate prior examination and medical indication. A video visit is not a shortcut around that patient-specific clinical judgment. For Schedule III ketamine, the federal telemedicine flexibility in effect through December 31, 2026 permits certain DEA-registered practitioners to prescribe Schedule II through V drugs by audio-video without a prior in-person examination, subject to its conditions and all other federal and state requirements. Treat that temporary rule as a dated branch of the service model, not as a permanent answer.

Build controlled-substance work into the clinical record

Controlled-substance handling is not merely an inventory task. It connects the patient assessment, prescribing or furnishing decision, receipt, storage, access, administration, dispensing, waste, reconciliation, diversion response, and patient follow-up.

California's CURES system has registration and consultation requirements for practitioners authorized to prescribe controlled substances. For Schedule II through IV drugs, consultation generally occurs before the first prescription, order, administration, or furnishing and at least every six months while treatment continues, subject to statutory exceptions. Decide which exception, if any, applies to the actual prescribing, administration, or on-premises-use model. Record the reason only when the applicable exception requires it.

Name who can order, receive, access, administer, reconcile, and waste the medication. Separate clinical authority from administrative access. Then test the record against a difficult event: a missing dose, a late shipment, an early refill request, an unexpected transfer of care, or a report of misuse.

Treat TMS as a device service with its own safety system

TMS is a device service. Do not assume its coverage, staffing, facility facts, or safety system are the same as a ketamine program. It uses an external device that delivers pulsed magnetic fields. The device's FDA-cleared labeling, instructions for use, and maintenance requirements matter more than a generic claim that the practice "offers TMS."

For each device, record the model, cleared indication, patient-selection and screening process, order, protocol-change authority, operator qualifications, treatment record, settings, maintenance, software version, location, service contract, and response to symptoms or device failure. The FDA's TMS guidance identifies device risks that include seizure, worsening depression or suicidality, hearing, electrical, electromagnetic, and overheating risks. The practice should build patient screening, trained operation, emergency response, and ongoing clinical assessment around the actual device and its instructions. FDA clearance and instructions for use are not a staffing credential or an insurance grant.

The person who runs a session is not necessarily the clinician who makes every clinical decision. Make the division of work clear. Who determines suitability? Who reviews a change in symptoms? Who responds to a seizure, a device alarm, or a missed course of care? Who can change the protocol? Those are clinical-system questions before they become an insurance question.

Do not guess at the facility question

A ketamine program does not automatically require an accredited outpatient surgery setting. California's threshold turns on the actual procedure and anesthesia plan. A physician and surgeon may not perform an outpatient procedure using anesthesia other than local anesthesia or peripheral nerve blocks at doses that have the probability of placing the patient at risk of loss of life-preserving protective reflexes unless the setting is one permitted by Health and Safety Code section 1248.1. Confirm the setting requirement before launch if the planned service reaches that threshold.

If the practice operates an accredited outpatient setting, its separate California requirements include an emergency system, a transfer or emergency route, clinical records, monitoring, discharge criteria, and two on-site staff while a patient remains in supervised care. One must be a physician or an ACLS-qualified licensed professional. Those setting rules do not automatically govern every ordinary office ketamine session.

Make crisis response work across settings

Behavioral-health practices need an explicit plan for suicidal thoughts or behavior, clinical deterioration, intoxication, agitation, medical instability, loss of contact, and a patient who leaves a monitored treatment. The plan should name the responsible clinician, the information available to that clinician, the emergency route, the handoff destination, the after-hours role, and the record of what happened.

Test the plan for three settings: a patient in the clinic, a patient after a monitored treatment, and a patient connecting by telehealth. A crisis instruction is not a handoff. The practice should know who owns the next clinical decision until a receiving clinician or emergency service takes responsibility.

Keep research and public claims in their own lanes

Off-label clinical prescribing is not automatically research. If the program conducts a clinical investigation, separately map the sponsor and investigator roles, IRB and informed-consent process, protocol and deviation reporting, investigational-product controls, legal entity, and research coverage. A research label does not turn ordinary treatment into a study or settle clinical responsibility.

Public claims need the same discipline. California prohibits false or misleading advertising, unjustified expectations of favorable results, and scientific claims without reliable peer-reviewed support. Review ketamine, TMS, outcome, subscription, and credential claims against the actual service and evidence before publishing them.

Keep entities, clinical control, and insurance in view

One brand may hide a professional medical practice, management company, telehealth platform, pharmacy relationship, device owner, research program, or property company. Begin with the entity chart and the contracts, then compare them with how care happens on an ordinary day.

California's Medical Board identifies decisions that a California-licensed physician must make or retain ultimate responsibility for or approval of, including patient care, clinical-competency staffing, patient-record control, payer-contract parameters, coding and billing procedures, and medical equipment. A management company can support administration. It cannot use a financial or technical arrangement to control clinical judgment.

Insurance is policy-specific. Ask the broker or insurer how the issued policy treats the actual legal entities, clinicians, psychiatric services, ketamine routes, compounded or home-use programs, esketamine, TMS devices, locations, telehealth states, research, and professional-services definitions. Read the named-insured definition, covered-person definition, exclusions, limits, defense terms, reporting duties, effective dates, and endorsements. Do not infer a coverage decision from a certificate, trade name, or prior application.

For claims-made professional liability coverage, dates also matter. The NAIC explains that claims-made coverage generally responds under the policy active when the claim is reported, subject to its terms and any extended reporting period. Retroactive or prior-acts dates, known-claim and related-claim provisions, notice, and extended-reporting terms can also matter. Preserve a dated record when the practice adds a drug route, device, home-use model, clinician, entity, or location.

Review the program before the next patient is scheduled

Review the clinical map and issued-policy record before the practice adds ketamine, esketamine, a route, a compounded product, a shipment model, a TMS device, an indication, a prescriber, a clinician, a telehealth state, a pharmacy, a platform, or a location. Revisit them after a protocol change, emergency event, diversion concern, device failure, patient complaint, or change in ownership.

The closing test is practical. A patient calls tonight after treatment and reports new confusion, severe distress, or a change in safety. Can the practice identify the responsible clinician, the exact product or device involved, the relevant record, the emergency route, the entity providing care, and the policy terms and reporting contact that govern the event? A program that can answer those questions is treating behavioral-health care as a real clinical system rather than a collection of services.

Ketamine, esketamine, and TMS are different clinical operations.